
NanoVibronix NAOV
Quarterly report 2025-Q3
added 11-14-2025
NanoVibronix General and Administrative Expenses 2011-2026 | NAOV
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses NanoVibronix
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.46 M | 3.92 M | 3.93 M | 5.06 M | 3.77 K | 3.82 M | 2.64 M | 2.08 M | 1.36 M | 747 K | 589 K | 366 K | 128 K | 87 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.06 M | 3.77 K | 2.01 M |
Quarterly General and Administrative Expenses NanoVibronix
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.4 M | 2.25 M | 1.34 M | - | 673 K | 716 K | 946 K | - | 796 K | 963 K | 1.02 M | - | 738 K | 1.16 M | 942 K | - | 801 K | 839 K | 1.02 M | - | 546 K | 1.31 M | 657 K | - | 533 K | 682 K | 1.8 M | - | 868 K | 454 K | 480 K | - | 387 K | 424 K | 593 K | - | 298 K | 197 K | 245 K | - | 208 K | 199 K | 126 K | - | 265 K | 151 K | -48 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.25 M | -48 K | 722 K |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
14.1 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
382 M | $ 12.07 | 0.33 % | $ 1.63 B | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
EDAP TMS S.A.
EDAP
|
5.9 M | $ 3.45 | 1.77 % | $ 129 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
Align Technology
ALGN
|
1.76 B | $ 171.87 | 0.74 % | $ 12.9 B | ||
|
AxoGen
AXGN
|
44.6 M | $ 32.64 | -5.23 % | $ 1.5 B | ||
|
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
15.1 M | - | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
Butterfly Network
BFLY
|
39.8 M | $ 4.13 | 0.49 % | $ 874 M | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
Bruker Corporation
BRKR
|
894 M | $ 36.74 | -0.05 % | $ 5.47 K | ||
|
BioSig Technologies
BSGM
|
67.5 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
6.89 B | $ 62.59 | -0.37 % | $ 92.7 B | ||
|
Alphatec Holdings
ATEC
|
499 M | $ 10.97 | 1.29 % | $ 1.65 B | ||
|
CONMED Corporation
CNMD
|
132 M | - | - | $ 1.06 B | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
16.5 M | $ 9.38 | 0.11 % | $ 266 M | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.59 | 1.2 % | $ 36.7 M | ||
|
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M | ||
|
Delcath Systems
DCTH
|
43.5 M | $ 9.7 | 0.73 % | $ 347 M | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
Edwards Lifesciences Corporation
EW
|
2.09 B | $ 81.19 | 0.17 % | $ 47.5 B | ||
|
Second Sight Medical Products
EYES
|
1.11 M | - | -0.97 % | $ 54.4 M | ||
|
Electromed
ELMD
|
39.3 M | $ 23.61 | 1.37 % | $ 200 M | ||
|
FONAR Corporation
FONR
|
23.5 M | $ 18.6 | 0.05 % | $ 122 M | ||
|
Globus Medical
GMED
|
1.18 B | $ 88.6 | 0.77 % | $ 12 B | ||
|
Helius Medical Technologies
HSDT
|
9.27 M | $ 1.9 | 2.15 % | $ 1.15 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
717 M | $ 9.31 | -2.31 % | $ 717 M | ||
|
Inogen
INGN
|
67.4 M | $ 6.36 | 2.42 % | $ 169 M | ||
|
Inspire Medical Systems
INSP
|
625 M | $ 54.14 | -1.55 % | $ 1.59 B | ||
|
IRIDEX Corporation
IRIX
|
7.73 M | $ 1.0 | 1.66 % | $ 16.9 M | ||
|
IRadimed Corporation
IRMD
|
17.8 M | $ 95.66 | -0.59 % | $ 1.22 B | ||
|
Integer Holdings Corporation
ITGR
|
212 M | $ 85.63 | -1.4 % | $ 2.97 B | ||
|
Invacare Corporation
IVC
|
227 M | - | - | $ 24.7 M | ||
|
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M |